tcga_identifiers.xlsx (10.1 kB)

Metadata record for the article: Germline RAD51B loss-of-function variants confer susceptibility to hereditary breast and ovarian cancers and result in homologous recombination-deficient tumors

online resource

posted on 2021-09-14, 09:31 authored by Jeremy Setton, Pier Selenica, Semanti Mukherjee, Rachna Shah, Isabella Pecorari, Biko McMillan, Isaac X Pei, Yelena Kemel, Ozge Ceyhan-Birsoy, Margaret Sheehan, Kaitlyn Tkachuk, David N. Brown, Liying Zhang, Karen Cadoo, Simon Powell, Britta Weigelt, Mark Robson, Nadeem Riaz, Kenneth Offit, Jorge S Reis-Filho, Diana Mandelker

This metadata record provides details of the data supporting the claims of the related article: “Germline RAD51B loss-of-function variants confer susceptibility to hereditary breast and ovarian cancers and result in homologous recombination-deficient tumors”.

The related study aimed to investigate whether loss of function variants in the RAD51 paralog, RAD51B, had any impact on susceptibility of breast and ovarian cancer.

Type of data: Clinical characteristics data; Sequence data from the National Cancer Institute Genomic Data Commons legacy archive; Immunoblotting data; Cell survival data; Flow cytometry data

Subject of data: Patients who consented to undergo somatic and germline analysis under an Institutional Review Board (IRB)-approved protocol at Memorial Sloan Kettering Cancer Center (MSKCC) and were profiled using the MSK-IMPACT assay.

Sample size: 19 breast and ovarian tumours from 18 patients; Matched normal DNA samples

Population characteristics: Patients with a RAD51B loss-of-function germline variant

Recruitment: Constitutively accrued MSKCC patients with a RAD51B loss-of-function germline variant.

Geographic location: United States of America

Trial registration number: NCT01775072

Data access

Non-identifying clinical characteristics data are openly available in Table 2 of the manuscript. Identifying information for the patients is not available to protect patient privacy.

The sequence data accessed for this study from the National Cancer Institute (NCI) Genomic Data Commons (GDC) legacy archive, are described in the file tcga_identifiers.xlsx, which is part of this figshare record.

The nonsynonymous somatic mutation sequence data identified in this study from 18 patients can be accessed from the cBioPortal repository https://identifiers.org/cbioportal:mixed_msk_tcga_2021

The immunoblotting images and cell survival data from the study can be found in Figure 4 of the related article, and in Figure S3 of the related article’s supplementary information file.

The flow cytometry data are openly available from https://github.com/jsetton1/npjBreastCancer_RAD51B.

Please note that the materials and reagents used in this study may be subject to an institutional material transfer agreement.

Corresponding author for this study

Diana Mandelker (mandelkd@mskcc.org)

Study approval

Institutional Review Board at Memorial Sloan Kettering Cancer Center (MSKCC)

Funding

Breast Cancer Research Foundation

Sarah Jenkins Fund

National Cancer Institute at the National Institutes of Health Paul Calabresi Career Development Award for Clinical Oncology (K12 CA184746)

National Cancer Institute at the National Institutes of Health Cancer Center Support Grant (P30 CA008747)

History

Research Data Support

This record was produced by Springer Nature’s Research Data Support service. This service focuses on maximising the findability and accessibility of the data, and does not involve peer review of data.